Search Results - "Coutre, S."

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL by Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C

“…In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared…”
Get full text

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial by DeAngelo, D J, George, T I, Linder, A, Langford, C, Perkins, C, Ma, J, Westervelt, P, Merker, J D, Berube, C, Coutre, S, Liedtke, M, Medeiros, B, Sternberg, D, Dutreix, C, Ruffie, P-A, Corless, C, Graubert, T J, Gotlib, J

“…Patients with advanced systemic mastocytosis (SM) (e.g. aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL))…”
Get full text

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia by RAWSTRON, A. C, VILLAMOR, N, EVAN, P. A. S, NATKUNAM, Y, COUTRE, S. E, AVERY, E. D, RASSENTI, L. Z, KIPPS, T. J, CALIGARIS-CAPPIO, F, KNEBA, M, BYRD, J. C, HALLEK, M. J, RITGEN, M, MONTSERRAT, E, HILLMEN, P, BÖTTCHER, S, GHIA, P, ZEHNDER, J. L, LOZANSKI, G, COLOMER, D, MORENO, C, GEUNA, M

“…The eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) predicts for improved outcome. However, the wide variety of MRD…”
Get full text

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia by Shustik, C., Bence-Bruckler, I., Delage, R., Owen, C. J., Toze, C. L., Coutre, S.

“…Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of…”
Get full text

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase by Cortes, J, Kim, D-W, Raffoux, E, Martinelli, G, Ritchie, E, Roy, L, Coutre, S, Corm, S, Hamerschlak, N, Tang, J-L, Hochhaus, A, Khoury, H J, Brümmendorf, T H, Michallet, M, Rege-Cambrin, G, Gambacorti-Passerini, C, Radich, J P, Ernst, T, Zhu, C, Van Tornout, J M A, Talpaz, M

“…Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this…”
Get full text

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia by Pollyea, D A, Kohrt, H E, Gallegos, L, Figueroa, M E, Abdel-Wahab, O, Zhang, B, Bhattacharya, S, Zehnder, J, Liedtke, M, Gotlib, J R, Coutre, S, Berube, C, Melnick, A, Levine, R, Mitchell, B S, Medeiros, B C

“…Acute myeloid leukemia (AML) is a disease of the elderly. Poor outcomes with standard therapies necessitate novel approaches. Outpatient regimens sufficiently…”
Get full text

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2 by Coutre, S. E., Barr, P. M., Owen, C., Robak, T., Tedeschi, A., Bairey, O., Burger, J. A., Hillmen, P., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, S., Szoke, A., Dean, J. P., Kipps, T. J., Ghia, P.

Get full text

Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine by EVANS, William E, YUEN YI HON, MURRAY, Jeffrey, QUINN, John, RAVINDRANATH, Y, RITCHEY, Kim, ROBERTS, William, ROGERS, Zora R, SCHIFF, Deborah, STEUBER, Charles, TUCCI, Fabio, KORNEGAY, Nancy, BOMGAARS, Lisa, KRYNETSKI, Eugene Y, RELLING, Mary V, COUTRE, Steve, HOLDSWORTH, Mark, JANCO, Robert, KALWINSKY, David, KELLER, Frank, KHATIB, Ziad, MARGOLIN, Judy

“…To assess thiopurine S-methyltransferase (TPMT) phenotype and genotype in patients who were intolerant to treatment with mercaptopurine (MP) or azathioprine…”
Get full text

FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA by Tedeschi, A., Burger, J., Barr, P.M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, S., Lal, I., Dean, J.P., Kipps, T.J.

Get full text

EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) by Tam, C.S., Byrd, J.C., O'Brien, S., Coutre, S., Barr, P.M., Furman, R.R., Kipps, T.J., Burger, J.A., Stevens, D., Sharman, J., Ghia, P., Flinn, I., Zhou, C., Ninomoto, J., James, D.F., Wierda, W.G.

Get full text

LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW‐UP by Montillo, M., Byrd, J.C., Hillmen, P., O'Brien, S., Barrientos, J.C., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Barr, P.M., Furman, R.R., Kipps, T.J., Thornton, P., Moreno, C., Pagel, J.M., Burger, J.A., Jones, J., Dai, S., Vezan, R., James, D.F., Brown, J.R.

Get full text

PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL by Sharman, J, Coutre, S, Furman, R, Cheson, B, Pagel, J, Hillmen, P, Barrientos, J, Zelenetz, A, Kipps, T, Flinn, I, Ghia, P, Hallek, M, Coiffier, B, O’Brien, S, Stilgenbauer, S

Get full text

Conversion of thrombin into an anticoagulant by protein engineering by Gibbs, C. S, Coutré, S. E, Tsiang, M, Li, W-X, Jain, A. K, Dunn, K. E, Law, V. S, Mao, C. T, Matsumura, S. Y, Mejza, S. Y, Paborsky, L. R, Leung, L. L. K

“…At sites of vascular injury, thrombin interacts with multiple procoagulant substrates, to mediate both fibrin clotting and platelet aggregation. But upon…”
Get full text

Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity in Vivo by Tsiang, M, Paborsky, L. R, Li, W.-X, Jain, A. K, Mao, C. T, Dunn, K. E, Lee, D. W, Matsumura, S. Y, Matteucci, M. D, Coutré, S. E, Leung, L. L. K, Gibbs, C. S

“…Previous alanine scanning mutagenesis of thrombin revealed that substitution of residues W50, K52, E229, and R233 (W60d, K60f, E217, and R221 in…”
Get full text

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome by Cools, Jan, DeAngelo, Daniel J, Gotlib, Jason, Stover, Elizabeth H, Legare, Robert D, Cortes, Jorges, Kutok, Jeffrey, Clark, Jennifer, Galinsky, Ilene, Griffin, James D, Cross, Nicholas C.P, Tefferi, Ayalew, Malone, James, Alam, Rafeul, Schrier, Stanley L, Schmid, Janet, Rose, Michal, Vandenberghe, Peter, Verhoef, Gregor, Boogaerts, Marc, Wlodarska, Iwona, Kantarjian, Hagop, Marynen, Peter, Coutre, Steven E, Stone, Richard, Gilliland, D. Gary

“…A fusion between the PDGFRA and FIP1L1 genes was found in some cases of the hypereosinophilic syndrome, a fatal disorder in which eosinophils invade and…”
Get full text

United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia by SOIGNET, Steven L, FRANKEL, Stanley R, SIEVERS, Eric L, COUTRE, Steven, DAHLBERG, Steve, ELLISON, Ralph, WARRELL, Raymond P, DOUER, Dan, TALLMAN, Martin S, KANTARJIAN, Hagop, CALLEJA, Elizabeth, STONE, Richard M, KALAYCIO, Matt, SCHEINBERG, David A, STEINHERZ, Peter

“…To determine the safety and efficacy of arsenic trioxide (ATO) in patients with relapsed acute promyelocytic leukemia (APL). Forty patients experiencing first…”
Get full text

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL by Woyach, Jennifer A, Ruppert, Amy S, Heerema, Nyla A, Zhao, Weiqiang, Booth, Allison M, Ding, Wei, Bartlett, Nancy L, Brander, Danielle M, Barr, Paul M, Rogers, Kerry A, Parikh, Sameer A, Coutre, Steven, Hurria, Arti, Brown, Jennifer R, Lozanski, Gerard, Blachly, James S, Ozer, Hatice G, Major-Elechi, Brittny, Fruth, Briant, Nattam, Sreenivasa, Larson, Richard A, Erba, Harry, Litzow, Mark, Owen, Carolyn, Kuzma, Charles, Abramson, Jeremy S, Little, Richard F, Smith, Scott E, Stone, Richard M, Mandrekar, Sumithra J, Byrd, John C

“…Among older patients with untreated chronic lymphocytic leukemia, treatment with ibrutinib, either alone or in combination with rituximab, was superior to…”
Get full text

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia by Burger, Jan A, Tedeschi, Alessandra, Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Bairey, Osnat, Hillmen, Peter, Bartlett, Nancy L, Li, Jianyong, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven, Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A, Janssens, Ann, Offner, Fritz, Mayer, Jiří, O’Dwyer, Michael, Hellmann, Andrzej, Schuh, Anna, Siddiqi, Tanya, Polliack, Aaron, Tam, Constantine S, Suri, Deepali, Cheng, Mei, Clow, Fong, Styles, Lori, James, Danelle F, Kipps, Thomas J

“…The Bruton's tyrosine kinase inhibitor ibrutinib was compared with the alkylating agent chlorambucil in patients with chronic lymphocytic leukemia. Ibrutinib…”
Get full text

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia by Byrd, John C, Brown, Jennifer R, O'Brien, Susan, Barrientos, Jacqueline C, Kay, Neil E, Reddy, Nishitha M, Coutre, Steven, Tam, Constantine S, Mulligan, Stephen P, Jaeger, Ulrich, Devereux, Steve, Barr, Paul M, Furman, Richard R, Kipps, Thomas J, Cymbalista, Florence, Pocock, Christopher, Thornton, Patrick, Caligaris-Cappio, Federico, Robak, Tadeusz, Delgado, Julio, Schuster, Stephen J, Montillo, Marco, Schuh, Anna, de Vos, Sven, Gill, Devinder, Bloor, Adrian, Dearden, Claire, Moreno, Carol, Jones, Jeffrey J, Chu, Alvina D, Fardis, Maria, McGreivy, Jesse, Clow, Fong, James, Danelle F, Hillmen, Peter

“…In this trial, patients with previously treated and relapsed chronic lymphoid leukemia who received ibrutinib had significantly improved progression-free…”
Get full text

Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed by Keating, M. J.

Get full text